Sarepta Roche

Sarepta cements its DMD throne with $1B+ gene t...

Alejandro Alvarez Paneque on LinkedIn: Update o...

Sarepta: Roche Partnership After The FDA's Turn...

Sarepta (SRPT) Seeks Label Expansion for DMD Ge...

Samantha Roche – Wayne Ballet

Roche Buys Ex-U.S. Rights to Sarepta DMD Gene T...

Roche, Sarepta collaborates; FDA approval for M...

Roche hands $1B to Sarepta in major return to g...

Matthew Gall on LinkedIn: Great day for Roche, ...

Roche and Sarepta Partner on Duchenne Muscular ...

Sarepta Therapeutics | Biopharmaceutical Compan...

Sarepta Therapeutics on LinkedIn: #rarediseaseday

Path to gene therapy approval in the UK – Sarep...

Roche halts testing of Sarepta Duchenne gene th...

Why Join Us | Roche

Meet Our Sarepta Children » Good Hope Inc

Roche-Sarepta deal a positive sign for Australi...

Sarepta

Alice He on LinkedIn: Roche Sarepta Therapeutics

Sarepta in $1.1 billion licensing deal with Roc...

Sarepta Signs Gene Therapy Agreement With Roche...

Roche Puts Up Historic $1.15B for Sarepta Duche...

Roche halts testing of Sarepta Duchenne gene th...

Sarepta Therapeutics on LinkedIn: #duchenne

Roche to pay Sarepta $1B upfront for DMD gene t...

Rx Rundown: Roche, Sarepta Therapeutics, Merck ...

Join Us | Careers at Sarepta Therapeutics

Sarepta/Roche Suspend Elevidys Gene Therapy Tri...

Sarepta Signs Gene Therapy Agreement With Roche...

Sarepta, Roche Present Promising Functional Dat...

Sarepta shares tumble as concerns mount over FD...

Sarepta - Conquering Columbus

Sarepta Therapeutics Announces Partnership with...

Sarepta DMD Gene Therapy SRP-9001 Gets Access t...

Roche and Sarepta Partner on Duchenne Muscular ...